A new treatment approach for HER2-positive cancers using nanotechnology
HER2-targeting transformable nanotherapeutic platform against HER2+ cancers
['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA AT DAVIS · NIH-10813697
This study is testing a new treatment that uses tiny particles to target and fight HER2-positive cancers, like certain types of breast and bladder cancer, by delivering special agents directly to the tumor to help boost the body’s immune response and improve the chances of recovery.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA AT DAVIS (nih funded) |
| Locations | 1 site (DAVIS, UNITED STATES) |
| Trial ID | NIH-10813697 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a novel nanotherapeutic platform that targets HER2-positive cancers, including breast and bladder cancers. The approach utilizes a peptide-based nano-agent that transforms at the tumor site to effectively suppress HER2 dimerization, which is crucial for tumor growth. By delivering immuno-stimulants directly to the tumor, this therapy aims to enhance tumor cell death and potentially lead to complete remission. Patients may benefit from a more effective treatment option that combines immunotherapy with targeted therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with HER2-positive breast or bladder cancers.
Not a fit: Patients with cancers that do not express HER2 or those with other types of malignancies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with HER2-positive cancers, potentially leading to improved survival rates.
How similar studies have performed: Other research has shown promising results with similar nanotherapeutic approaches in targeting cancer cells, indicating potential for success in this novel application.
Where this research is happening
DAVIS, UNITED STATES
- UNIVERSITY OF CALIFORNIA AT DAVIS — DAVIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LAM, KIT S — UNIVERSITY OF CALIFORNIA AT DAVIS
- Study coordinator: LAM, KIT S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Bladder Cancer, Urinary Bladder Cancer